Travere Therapeutics (TVTX) AI Stock Analysis

• Market Cap: $3.15B
• Dividend Yield: N/A
• Average Volume (3M): 1.91M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.28
• Revenue Growth: 114.22%
• EPS Growth: 77.02%
• Country: US
• Employees: 385
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.28
• Shares Outstanding: 89,472,330
• 10 Day Avg. Volume: 2,204,866
• 30 Day Avg. Volume: 1,905,408
• PEG Ratio: -0.02
• Price to Book (P/B): 23.26
• Price to Sales (P/S): 5.89
• P/FCF Ratio: -4.06
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $36.62
• Price Target Upside: 4.15% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 16

• Rating: 54 Neutral
• Price Target: $36.00 ▲(2.39% Upside)

Travere Therapeutics' stock score is primarily influenced by its strong earnings call performance, highlighting significant sales growth and potential FDA approvals. However, financial performance challenges, including high debt and negative cash flows, weigh heavily on the score. Technical analysis shows strong momentum, but overbought conditions suggest caution. Valuation concerns due to negative earnings further impact the overall score.

Positive Factors

Revenue Growth

The substantial increase in FILSPARI sales demonstrates strong market demand and effective commercialization strategies, indicating robust revenue growth potential.

Regulatory Advancements

Regulatory advancements enhance product accessibility and safety perception, potentially increasing market adoption and supporting long-term growth.

Pipeline Development

Potential FDA approval for FSGS represents a significant opportunity to address unmet medical needs, expanding the company's market presence and product portfolio.

Negative Factors

High Debt Levels

High leverage can strain financial resources and limit strategic flexibility, posing risks to long-term financial stability and growth.

Negative Cash Flow

Negative cash flow highlights operational inefficiencies and financial strain, potentially impacting the company's ability to invest in growth and innovation.

Profitability Challenges

Persistent profitability issues may hinder the company's ability to generate sustainable returns, affecting long-term financial health and investor confidence.

Travere Therapeutics Business Overview & Revenue Model

Company Description

Travere Therapeutics, Inc. is a biotechnology company focused on the development and commercialization of innovative therapies for rare diseases. The company specializes in addressing unmet medical needs for patients with conditions such as kidney diseases and metabolic disorders. Travere's core products include approved therapeutics such as Filspari (sparsentan) and its pipeline candidates aimed at treating various rare diseases, leveraging its expertise in drug development and clinical research.

How the Company Makes Money

Travere Therapeutics generates revenue primarily through the sale of its approved pharmaceutical products, particularly Filspari, which is marketed for the treatment of IgA nephropathy. The company also earns revenue through collaborations and partnerships with other pharmaceutical companies, which may include milestone payments and royalties based on the sales of products developed in conjunction with these partners. Additionally, Travere may receive funding through grants and research contracts aimed at supporting its drug development initiatives.

Travere Therapeutics Financial Statement Overview

Summary

Travere Therapeutics shows strong revenue growth and gross profit margins, but faces significant profitability and leverage challenges. High debt levels and negative cash flows pose financial risks, requiring careful management to achieve sustainable growth and profitability.

Income Statement

Travere Therapeutics shows a strong gross profit margin of 92.69% TTM, indicating efficient cost management. However, the company faces challenges with negative net profit and EBIT margins, reflecting ongoing losses. Revenue growth is positive at 22.06% TTM, suggesting potential for future improvement, but the consistent negative margins highlight profitability issues.

Balance Sheet

The company has a high debt-to-equity ratio of 12.20 TTM, indicating significant leverage and potential financial risk. Return on equity is negative, reflecting ongoing losses and challenges in generating shareholder value. The equity ratio is low, suggesting limited equity financing relative to total assets.

Cash Flow

Operating cash flow and free cash flow are both negative, indicating cash burn. However, the free cash flow to net income ratio is above 1, suggesting that cash outflows are somewhat aligned with accounting losses. The negative free cash flow growth rate of -32.51% TTM highlights increasing cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	435.83M	233.18M	145.24M	212.02M	227.49M	198.32M
Gross Profit	248.20M	181.88M	133.79M	204.43M	220.71M	192.19M
EBITDA	-41.90M	-265.77M	-326.25M	-299.42M	-186.68M	-143.95M
Net Income	-88.54M	-321.55M	-111.40M	-278.48M	-180.09M	-169.43M
Balance Sheet
Total Assets	538.58M	594.13M	788.91M	672.59M	776.63M	607.44M
Cash, Cash Equivalents and Short-Term Investments	254.53M	370.70M	566.85M	450.25M	552.88M	361.59M
Total Debt	329.75M	401.58M	404.78M	407.49M	261.99M	215.34M
Total Liabilities	465.02M	535.05M	588.10M	629.73M	474.52M	396.23M
Stockholders Equity	73.56M	59.08M	200.81M	42.85M	302.11M	211.21M
Cash Flow
Free Cash Flow	-68.55M	-338.69M	-322.28M	-214.85M	-38.94M	-162.59M
Operating Cash Flow	-58.61M	-237.47M	-280.02M	-186.29M	-14.79M	-42.74M
Investing Cash Flow	52.42M	99.33M	55.78M	-32.55M	-137.62M	-61.33M
Financing Cash Flow	78.97M	139.42M	218.75M	117.57M	231.68M	127.71M

Travere Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 35.16
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TVTX, the sentiment is Positive. The current price of 35.16 is above the 20-day moving average (MA) of 27.84, above the 50-day MA of 24.51, and above the 200-day MA of 19.56, indicating a bullish trend. The MACD of 1.99 indicates Negative momentum. The RSI at 82.97 is Negative, neither overbought nor oversold. The STOCH value of 80.88 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TVTX.

Travere Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARQT	―	$3.10B	―	-28.17%	―	129.21%	80.35%
TARS	―	$2.90B	―	-31.46%	―	254.45%	48.06%
TVTX	―	$3.15B	―	-410.78%	―	114.22%	77.02%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RXRX	―	$2.40B	―	-86.34%	―	30.14%	-10.08%
GLPG	―	$2.10B	―	-10.10%	―	―	―
IRON	―	$3.22B	―	-26.36%	―	―	-22.19%

Travere Therapeutics Corporate Events

Travere Therapeutics’ Strong Quarter and Future Prospects

Travere Therapeutics, Inc. recently held its earnings call, revealing a strong quarter marked by significant growth in FILSPARI sales, potential FDA approval for new indications, and successful manufacturing advancements. Despite these achievements, the company faces challenges from seasonal trends and a competitive market landscape.

Travere Therapeutics Reports Strong Q3 2025 Growth

Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing and delivering therapies for rare diseases, with a notable emphasis on nephroprotective treatments.

Travere Therapeutics’ Sparsentan Study: A Potential Game-Changer in Kidney Transplant Treatment

Travere Therapeutics, Inc. is conducting a clinical study titled ‘A Multicenter, Open-label Single Arm Study to Evaluate the Safety and Efficacy of Sparsentan in Posttransplant Immunoglobulin A Nephropathy (IgAN) or Focal Segmental Glomerulosclerosis (FSGS) (SPARX)’. The study aims to assess the safety and efficacy of sparsentan tablets in treating proteinuria in patients who have undergone kidney transplantation, with a focus on IgAN and FSGS conditions.

Travere Therapeutics Advances Sparsentan Study in Pediatric Kidney Diseases

Travere Therapeutics, Inc. is conducting a clinical study titled A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects With Selected Proteinuric Glomerular Diseases. The study aims to assess the safety, efficacy, and tolerability of sparsentan, focusing on its impact on proteinuria in children with specific kidney conditions over a 108-week period. This research is significant as it targets rare pediatric kidney diseases, potentially offering a new treatment option.

Travere Therapeutics Advances Phase 3 Study for Rare Genetic Disorder Treatment

Study Overview: Travere Therapeutics, Inc. is conducting a Phase 3 long-term extension study titled ENSEMBLE to assess the safety, tolerability, and efficacy of Pegtibatinase in participants aged 5 to 65 with classical homocystinuria (HCU) due to cystathionine beta synthase deficiency. This study aims to provide crucial data on the long-term effects of Pegtibatinase, a promising treatment for this rare genetic disorder.

Travere Therapeutics’ Study on Homocystinuria: A Closer Look at the ACAPPELLA Study

Travere Therapeutics, Inc. is conducting a study titled ‘A Multicenter, Observational, Prospective, Natural History Study of Homocystinuria Due to Cystathionine Beta-synthase Deficiency in Pediatric and Adult Patients (ACAPPELLA)’. The study aims to understand the clinical progression of homocystinuria in patients aged 1 to 65 under current management practices, providing valuable insights into this condition.

FDA Drops Advisory Committee for Travere’s FILSPARI Review

On September 10, 2025, Travere Therapeutics announced that the FDA has decided an advisory committee is no longer needed for the review of the supplemental New Drug Application for FILSPARI in treating FSGS. The application remains under review with a target action date of January 13, 2026. If approved, FILSPARI would be the first medication indicated for FSGS, a serious kidney disorder. The drug has shown promising results in reducing proteinuria in clinical trials, which is significant for patients as it lowers the risk of kidney failure. The studies supporting FILSPARI’s application demonstrated its efficacy and safety, with results published in the New England Journal of Medicine indicating a meaningful clinical benefit.

The most recent analyst rating on (TVTX) stock is a Buy with a $47.00 price target. To see the full list of analyst forecasts on Travere Therapeutics stock, see the TVTX Stock Forecast page.

Travere Therapeutics Earnings Call Highlights FILSPARI Success

Travere Therapeutics, Inc. recently held its earnings call, showcasing a robust commercial performance for its leading product, FILSPARI. The call highlighted significant growth in sales, positive clinical data, and international expansion efforts. Despite challenges such as potential generic competition for THIOLA and regulatory uncertainties for FILSPARI’s approval in FSGS, the overall sentiment was optimistic, driven by FILSPARI’s strong market performance and potential.

Travere Therapeutics Reports Strong Q2 2025 Growth

Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing and delivering life-changing therapies for patients with rare diseases. The company recently reported its second quarter 2025 financial results, highlighting significant growth in net product sales, particularly for its drug FILSPARI (sparsentan), which saw a 165% increase year-over-year.